Bruce & Co’s IGM Biosciences IGMS Stock Holding History

Bruce & Co’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$115K	–	42
2025 Q1	$115K	Hold	100,000	–	–	0.04%	42
2024 Q4	$611K	Hold	100,000	–	–	0.2%	35
2024 Q3	$1.65M	Hold	100,000	–	–	0.48%	25
2024 Q2	$687K	Buy	100,000 +35,000	+54%	+$299K	0.23%	33
2024 Q1	$627K	Hold	65,000	–	–	0.21%	34
2023 Q4	$540K	Sell	65,000 -55,000	-46%	-$319K	0.19%	33
2023 Q3	$1M	Buy	120,000 +65,000	+118%	+$551K	0.34%	28
2023 Q2	$507K	Hold	55,000	–	–	0.14%	33
2023 Q1	$756K	Hold	55,000	–	–	0.21%	30
2022 Q4	$936K	Hold	55,000	–	–	0.24%	28
2022 Q3	$1.25M	Hold	55,000	–	–	0.34%	28
2022 Q2	$991K	Hold	55,000	–	–	0.23%	29
2022 Q1	$1.47M	Hold	55,000	–	–	0.3%	27
2021 Q4	$1.61M	Hold	55,000	–	–	0.32%	26
2021 Q3	$3.62M	Hold	55,000	–	–	0.77%	21
2021 Q2	$4.58M	Buy	+55,000	New	+$4.07M	0.87%	21

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bruce & Co's IGMS Position: Q2 2025 in Review

Bruce & Co sold out of IGM Biosciences (IGMS) in Q2 2025, closing a stake of 100,000 shares — an estimated $115K sold.

Bruce & Co first reported a position in IGMS in Q2 2021 and held it in 16 quarters. The position peaked at $4.58M in Q2 2021. 66 funds tracked by Wall St. Rank hold IGMS as of Q2 2025.

Bruce & Co reported no remaining IGM Biosciences position as of Q2 2025 after selling out during the quarter.
Bruce & Co sold 100,000 IGM Biosciences shares in Q2 2025, an estimated $115K.
Bruce & Co first reported a position in IGM Biosciences in Q2 2021 and held it in 16 quarters.
Bruce & Co's IGM Biosciences position peaked at $4.58M in Q2 2021.
66 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2025.

Based on Bruce & Co's 13F filing for Q2 2025, filed 14 Aug 2025.